Optimizerx Corporation (OPRX)
NASDAQ:OPRX
Want to see OPRX full AI Analyst Report?
OPRX Stock Chart & Stats
$7.17
-$1.11(-19.07%)
At close: 4:00 PM EST
$7.17
-$1.11(-19.07%)
Day’s Range― - ―
52-Week Range$5.54 - $22.25
Previous CloseN/A
Volume200.46K
Average Volume (3M)488.11K
Market Cap
$125.71M
Enterprise Value$129.76M
Total Cash (Recent Filing)$23.36M
Total Debt (Recent Filing)$26.10M
Price to Earnings (P/E)44.3
Beta1.95
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding18,762,203
10 Day Avg. Volume462,507
30 Day Avg. Volume488,107
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda7.92
Forecast
1Y Price Target
$15.20Price Target Upside111.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.97
Revenue Forecast (FY)$121.63M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Capital ReturnCompany reduced outstanding term loan debt and announced a share repurchase program, strengthening financial flexibility and supporting potential shareholder value.
Long-term Revenue OutlookAnalyst highlights that management raised revenue expectations for later periods to offset a weaker near-term outlook while keeping full-year targets largely unchanged, signaling confidence in the company's longer-term revenue trajectory.
Profitability And MarginsCompany delivered results that exceeded analyst expectations across key operating metrics, with strong gross margin expansion supporting adjusted profitability well above forecasts.
Bears Say
Industry Consolidation Disrupting Ad BudgetsA merger among major advertising agencies disrupted pharma advertising spend patterns, creating headwinds for revenue as budgets are reallocated and decision cycles slow.
Near-term Revenue PressureAnalyst lowered near-term revenue forecast due to a steeper ramp and macro headwinds in digital pharmaceutical marketing that are prompting manufacturers to cut marketing spending, pressuring short-term top-line performance.
Pricing Policy Uncertainty And Customer CautionManagement cited Most Favored Nation pricing uncertainty as a source of market volatility that is causing customers to be more cautious with discretionary spending and to shorten contract commitments.
OptimizeRx News
OPRX FAQ
What was Optimizerx Corporation’s price range in the past 12 months?
Optimizerx Corporation lowest stock price was $5.54 and its highest was $22.25 in the past 12 months.
What is Optimizerx Corporation’s market cap?
Optimizerx Corporation’s market cap is $125.71M.
When is Optimizerx Corporation’s upcoming earnings report date?
Optimizerx Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 93 days.
How were Optimizerx Corporation’s earnings last quarter?
Currently, no data Available
Is Optimizerx Corporation overvalued?
According to Wall Street analysts Optimizerx Corporation’s price is currently Undervalued.
Does Optimizerx Corporation pay dividends?
Optimizerx Corporation does not currently pay dividends.
What is Optimizerx Corporation’s EPS estimate?
Optimizerx Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Optimizerx Corporation have?
Optimizerx Corporation has 18,762,203 shares outstanding.
What happened to Optimizerx Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Optimizerx Corporation?
Currently, no hedge funds are holding shares in OPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OptimizeRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.20 (111.99% Upside)
$15.20 (111.99% Upside)
Blogger Sentiment
Bullish
OPRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.14%
12-Months-Change
Fundamentals
Return on Equity
4.22%
Trailing 12-Months
Asset Growth
3.36%
Trailing 12-Months
Company Description
Optimizerx Corporation
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
OPRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial performance for 2025: strong cash generation, improved profitability, high net revenue retention (116%), productivity gains, meaningful DAAP momentum and a $10M share repurchase authorization. However, management flagged near-term top-line risks driven by a market shift away from managed services, conservative client behavior tied to MFN negotiations, shorter contract durations, and a Q4 gross margin mix that is unlikely to repeat. Guidance for 2026 is conservative on revenue (flat to modestly higher) while maintaining healthy adjusted EBITDA expectations, reflecting a focus on profitability and cash usage for debt reduction and opportunistic buybacks. Overall, the positives around profitability, cash flow, recurring-revenue progress and customer traction outweigh the near-term revenue headwinds.View all OPRX earnings summariesOPRX Stock 12 Month Forecast
Average Price Target
$15.20
▲(111.99% Upside)
Technical Analysis
Ownership Overview
6.46% Insiders
19.17% Mutual Funds
1.07% Other Institutional Investors
62.87% Public Companies and
Individual Investors